Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon W Gribble

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
The Journal of Organic Chemistry|June 26, 1996
Stereodynamics of 9,11-Diphenyl-10-azatetracyclo[6.3.0.0.(4,11)0.(5,9)]undecanes. Highly Restricted Nitrogen Inversion and Isolated Phenyl Rotation. X-ray Crystallographic, Dynamic NMR, and Molecular Mechanics StudiesGordon W. Gribble, Frank L. Switzer, John H. Bushweller, et al.
The Journal of Biological Chemistry|August 25, 2005
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancerIsmael Samudio, Marina Konopleva, Numsen Hail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268Karen Liby, Renee Risingsong, Darlene B Royce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivoAndrew E Place, Nanjoo Suh, Charlotte R Williams, et al.
Molecular Cancer Therapeutics|July 11, 2007
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activitiesKaren Liby, Tadashi Honda, Charlotte R Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stressAlbena T Dinkova-Kostova, Karen T Liby, Katherine K Stephenson, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2019
First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitorsYangxiong Li, Jessi J Gardner, Katherine R Fortney, et al.
Molecular Cancer Therapeutics|May 17, 2008
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesisKaren Liby, Candice C Black, Darlene B Royce, et al.
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
The Journal of Organic Chemistry|June 26, 1996
Stereodynamics of 9,11-Diphenyl-10-azatetracyclo[6.3.0.0.(4,11)0.(5,9)]undecanes. Highly Restricted Nitrogen Inversion and Isolated Phenyl Rotation. X-ray Crystallographic, Dynamic NMR, and Molecular Mechanics StudiesGordon W. Gribble, Frank L. Switzer, John H. Bushweller, et al.
The Journal of Biological Chemistry|August 25, 2005
2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancerIsmael Samudio, Marina Konopleva, Numsen Hail, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268Karen Liby, Renee Risingsong, Darlene B Royce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivoAndrew E Place, Nanjoo Suh, Charlotte R Williams, et al.
Molecular Cancer Therapeutics|July 11, 2007
Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activitiesKaren Liby, Tadashi Honda, Charlotte R Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stressAlbena T Dinkova-Kostova, Karen T Liby, Katherine K Stephenson, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2019
First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitorsYangxiong Li, Jessi J Gardner, Katherine R Fortney, et al.
Molecular Cancer Therapeutics|May 17, 2008
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesisKaren Liby, Candice C Black, Darlene B Royce, et al.
Cancer Research|March 22, 2003
Synthetic triterpenoids enhance transforming growth factor beta/Smad signalingNanjoo Suh, Anita B Roberts, Stephanie Birkey Reffey, et al.
Cancer Research|June 3, 2005
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signalingKaren Liby, Thomas Hock, Mark M Yore, et al.
Pageof 8